The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?
But the pace of biopharma asset deals dips. Are the two trends related?
Biomarkers and precise targeting could help the anti-TGF-β1 antibody SRK-181 succeed where bintrafusp failed, the group hopes.
Lilly pips Pfizer to the big pharma top spot on share price performance, while Covid-19 drives the largest risers elsewhere.
The stock crashed on Friday as balstilimab’s US filing was pulled – an event that had been entirely foreseeable.